Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Indoleamine 2,3-dioxygenase 1 (IDO-1) is overexpressed in various human carcinomas.
• Adrenocortical carcinoma (ACC) has a poor prognosis due to limited effective treatments.
• Investigating IDO-1 expression in human ACC is crucial for developing new therapies.

Purpose of the Study:

• To determine the expression of IDO-1 in human ACC tissues.
• To explore the association of IDO-1 expression with tumor characteristics and immune markers.
• To evaluate IDO-1 as a potential therapeutic target for ACC.

Main Methods:

• Analysis of 53 adrenal tissue samples including ACC, adrenal adenoma (AA), and normal adrenal.
• Immunohistochemistry used to detect IDO-1 expression in cytoplasmic and stromal compartments.
• Assessment of tumor characteristics, PD-L1, PD-L2, and CD8+ T-lymphocyte expression.

Main Results:

• IDO-1 was expressed in tumor tissue in 22 of 32 ACC samples.
• IDO-1 expression was significantly increased in the stromal tissue of ACC compared to AA (P=0.001).
• IDO-1 expression correlated with PD-L2 expression (P=0.034) and CD8+ T-lymphocyte infiltration (P=0.028) in ACC.

Conclusions:

• IDO-1 is expressed in a majority of ACC samples.
• IDO-1 expression in ACC is linked to PD-L2 and CD8+ T-lymphocyte infiltration.
• IDO-1 inhibition, potentially combined with PD-1 inhibition, represents a promising therapeutic strategy for ACC.